Keith T. Flaherty, M.D.

Director of Clinical Research & Richard Saltonstall Chair in Oncology, MGH Cancer Center

Professor of Medicine, Harvard Medical School

Oncogene targeted therapy, cancer immunotherapy, early drug development


BS – Yale University

MD – Johns Hopkins University

Residency – Brigham & Women’s Hospital (Harvard Medical School)

Postdoctoral Fellow – University of Pennsylvania


NCI Cancer Therapeutics Evaluation Program Michaele Christian Oncology Development Award and Lectureship, 2015

NCI Board of Scientific Advisors, 2018 | Chair as of 2021

AACR Board of Directors, 2018

Society for Melanoma Research Lifetime Achievement Award, 2019

OncLive Giants of Cancer Care, 2020


Co-Founder: Loxo Oncology (acquired by Lily), Strata Oncology, X4 Pharmaceuticals, Apricity, C-Reveal, and Scorpion Therapeutics

Board of Directors: Loxo Oncology, Scorpion Therapeutics, Strata Oncology, Checkmate Pharmaceuticals (acquired 2022), Clovis Oncology, Kinnate Biopharma

Scientific Advisory Board: PIC Therapeutics, Apricity, Tvardi, ALX Oncology, xCures, Monopteros, Vibliome, Soley Therapeutics, Quanta Therapeutics, and intrECate

MEMBER OF Investment Committee

Associated Portfolio Companies

No items found.